Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MEETINGS - Molecular & Genetic Diagnostics: Profiting from Novel Diagnostics that Assess Disease Risk, Disease Presence & Treatment Response (UK) October 1999:

This article was originally published in Clinica

Executive Summary

IBC Conferences will hold a meeting on Molecular & Genetic Diagnostics: Profiting from Novel Diagnostics that Assess Disease Risk, Disease Presence & Treatment Response in London on October 4-5. Dr Uwe Bicker, executive chairman and director of Dade Behring and president of the European Diagnostic Manufacturers Association (EDMA), will present the keynote speech on growth & shift in the diagnostics industry. Representatives from companies including Roche Molecular Systems, Shield Diagnostics and Nycomed Amersham Imaging will discuss some of the latest developments in this field. For more details contact IBC in the UK. Tel: +44 20 7453 5496. Fax: +44 20 7636 6858. Website: www.ibc-uk.com/it1135

You may also be interested in...



QUOTED. 4 December. Eric Borin.

Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.

Pfizer’s Expected 2020 COVID-19 Vaccine Production Fell By 50% After Scaleup Delays

Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.

Azurity’s Xatmep Promotional Email To Healthcare Professionals Gets Dinged By US FDA

In second letter this year targeting email communications, OPDP says that putting the methotrexate oral solution’s risk information below the signature block does not offer ‘prominence and readability’ comparable to the information on the drug’s effectiveness for the treatment of acute lymphoblastic leukemia that was in the body of the email.

Topics

UsernamePublicRestriction

Register

OM006664

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel